Iantrek
Elkins Park, US · Founded 2019 · Delaware corporation · 7 known investors
Iantrek develops micro-interventional surgical technology using allogeneic biotissue to create a category it calls Bio-intervention for treating chronic eye disease. Its products target ophthalmic surgeons addressing conditions such as glaucoma through uveoscleral and trabecular procedures.
BiotechHealthtechMedical Devices
Founders & leadership
Iantrek was founded in 2019 by Tsontcho Ianchulev and Sean Ianchulev.
TI
Tsontcho IanchulevCo-founder
SI
Sean IanchulevFounder & Chairman of the Board (CMO)
MH
Michael HaydinExecutive
Board
JK
FT
Farrell TysonBoard director
SB
RW
Robert WeinrebBoard director
MM
Marc-Andre MarcotteBoard director
JM
James MazzoBoard director
AC
Andrew CorleyBoard director
Investors · 7
aMoon✓ verifiedRa'anana
Visionary Ventures✓ verifiedNewport Beach · $5M – $15M
Canaan Partners✓ verifiedStamford · $500K – $20Mvia Stephen Bloch · board
Civilization Ventures Management, LlcTiburon · $1M – $10M
FemHealth VenturesShort Hills
JSD Capital, LLCNew York · $10Mvia Jordan S. Davis · inferred
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
Reported raises · per SEC filings
Form D private placements$58.2M disclosed across 4 rounds · 2020–2025
▶$34.7MraisedAug 2025 · 21 investors · BiotechnologyRule 506(b)
▶$34.7MraisedAug 2025 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tsontcho IanchulevExecutive Officer, Director
- Todd SoneDirector
- James MazzoDirector
- Adam SzaronosExecutive Officer, Director
- Casey TanseyDirector
- Robert WeinrebDirector
- Marc-Andre MarcotteDirector
- Jeffry K. WeinhuffDirector
- Michael HaydinExecutive Officer
- Farrell TysonDirector
- Offering amount
- $42M
- Amount sold
- $34.7M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
▶$2.8MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HaydinExecutive Officer
- Robert WeinrebDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Jeffry K WeinhuffDirector
- Farrell TysonDirector
- James MazzoDirector
- Offering amount
- $5.5M
- Amount sold
- $2.8M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedAug 2022 · 25 investors · BiotechnologyRule 506(b)
▶$15.4MraisedAug 2022 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael George Haydin, IVExecutive Officer
- James MazzoDirector
- Jeffrey K. WeinhuffDirector
- Farrell TysonDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Robert WeinrebDirector
- Offering amount
- $25M
- Amount sold
- $15.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5.2MraisedOct 2020 · 29 investors · BiotechnologyRule 506(b)
▶$5.2MraisedOct 2020 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WeinrebDirector
- James MazzoDirector
- Jeffry K WeinhuffDirector
- Andrew CorleyDirector
- Tsontcho IanchulevExecutive Officer, Director
- Stephen BlochDirector
- Michael HaydinExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Iantrek went on to found or lead other companies.
Competitors · 3
by search overlapHealio23 shared keywordsHealio provides medical news, clinical data, and continuing medical education (CME) for healthcare professionals across specialties such as infectious disease and hepatology. It covers topics including biliary diseases, Ebola, and emerging outbreaks.
Glaukos22 shared keywordsGlaukos develops ophthalmic therapies for chronic eye diseases, including corneal cross-linking for keratoconus, glaucoma treatments, and sustained-release drug delivery platforms for retinal diseases. It serves ophthalmic surgeons and patients worldwide with its portfolio of medical treatments and devices.
Massdevice17 shared keywordsMassDevice is a news and media outlet covering the medical device industry, publishing articles, special reports, and white papers on medtech companies, products, and regulatory topics such as FDA 510(k) submissions. It serves medical device professionals with industry news and analysis.
Companies competing with Iantrek for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Iantrek do?
- Iantrek develops micro-interventional surgical technology using allogeneic biotissue to create a category it calls Bio-intervention for treating chronic eye disease. Its products target ophthalmic surgeons addressing conditions such as glaucoma through uveoscleral and trabecular procedures.
- Who founded Iantrek?
- Iantrek was founded by Tsontcho Ianchulev, Sean Ianchulev in 2019.
- Who are Iantrek's investors?
- Iantrek's investors include aMoon, Visionary Ventures, Canaan Partners, Civilization Ventures Management, Llc, FemHealth Ventures, JSD Capital, LLC, US Venture Partners.
- How much funding has Iantrek raised?
- Iantrek has disclosed $58.2M raised across 4 rounds.
- Where is Iantrek headquartered?
- Iantrek is headquartered in Elkins Park, US.